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Chapter 1 
INTRODUCTION TO PIKROMYCIN AND PIKC 
The 2010 Nobel Prize in Chemistry was awarded to Heck, Suzuki, and Negishi, 
and prior to that, the last ‘organic’ chemist(s) to be awarded a Noble Prize were Robert 
Grubbs, Richard Schrock, and Yves Chauvin.  The common theme amongst recent 
winners in the organic division is organometallic chemistry.  Each developed or had a 
significant contribution towards bringing transition metal catalyzed reactions to 
widespread use.  Mechanistic studies and/or studies towards developing a fundamental 
understanding of transition metals paved the way for current usage of transition metals by 
industrial and academic chemists alike.   
During the course of millions of years of evolution, enzymes have become 
‘master’ organic chemists.  Enzymes are capable of transformations a traditional chemist 
can currently only dream about.  Generations of students were trained that enzyme’s 
exquisite selectivity was due to rigid substrate specificity.  The ‘Lock and Key’ or 
‘Induced Fit’ hypothesis suggested that enzymes change their active site to accommodate 
one, and only one substrate.1 Indeed many enzymes conform to the notion of one 
substrate, one product; however contemporary studies have identified several enzymes 
countering the ‘one substrate, one enzyme dogma.2   
The pikromycin biosynthetic pathway is a unique polyketide biosynthetic 
pathway.  The enzymes found within the pathway uniquely produce several substrates of 
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varying ring size and functionalty.3  Polyketides share a common biosynthetic logic, 
whereby iterative chain elongation followed by reductive processing
produces long linear chains that are often cyclized by dedicated enzymes into 
macrocyclic compounds;4-6 although linear polyketides are known.7  Seminal studies 
conducted on the erythromycin biosynthetic pathway established the modular nature of 
polyketide biosynthesis.8-11  Based upon the erythromycin biosynthesis model studies the 
field of combinatorial biosynthesis blossomed.  The genomes for polyketide biosynthetic 
enzymes are clustered together; with dedicated enzymes performing specific tasks in an 
assembly-line fashion.  Unfortunately early applications of the ‘plug and play’ approach, 
whereby modules and domains from distinct biosynthetic pathways were traded, 
removed, and added, were only modestly successful.  Efforts involving addition, 
elimination, or substitution of individual catalytic domains produced an impressive 
number of natural product analogs; however the analogs were often produced in poor 
yield and more frequently not at all.12-14  The potential utility for using polyketide 
biosynthetic enzymes is astonishing; theoretical estimates hypothesize that polyketide 
biosynthetic pathways have the ability to generate hundreds of millions of compounds.15  
However, studies aimed at basic understanding must be conducted to fill in large 
knowledge gaps.  The pikromycin biosynthetic pathway can serve as a model system to 
understand enzymes with substrate flexibility. 
Pikromycin was first isolated in 1951, and has historical significance as the first 
ketolide antibiotic isolated.16  Although itself not clinically useful, the enzymes found 
within the pathway hold tremendous promise.  Several decades after initial isolation the 
Sherman laboratory reported the cloning and genetic sequence of the pikromycin 
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biosynthetic gene cluster from S. venezuelae ATCC 15439.17  Subsequent analysis of the 
60-kb of DNA sequence yielded the identification of 18 discrete genes, which were 
further subdivided into five separate loci:  PKS (pikA), desosamine biosynthesis (des), 
cytochrome P450 hydrolase (PikC), a transcriptional activator (pikD), and a resistance 
locus (PikR).17   
The PikA gene locus encodes for five polypeptide chains (PikAI-PikAV).  These 
five polypeptide chains represent a type I modular polyketide synthase.  The first four 
polypeptides, PikAI-PikAIV, are where the single loading modules and six PKS chain 
elongation modules that are responsible for synthesis of the linear chain elongation 
intermediates and subsequent macrolactone rings are found.  The final two modules are 
monomodules and are therefore contained on separate polypeptide chains; whereas the 
first three modules are di-domains.  The final polypeptide, PikAV is a type II 
thioesterase, the function of which remains controversial.  Preliminary investigations 
suggest type II thioesterase serves an editing role during PKS biosynthesis.18   On the 
basis of gene disruption studies, the Sherman lab demonstrated the unique ability of the 
pikromycin thioesterase to produce both a 12- and a 14-macrolactone.19   For over a 
decade, the Sherman laboratory has studied the PKS portion of pikromycin biosynthesis 
and has made several noteworthy conclusions and hypotheses.  Briefly the Sherman 
laboratory has demonstrated that understanding polyketide biosynthesis requires full 
length substrates, the pikromycin thioesterase is remarkably promiscuous, the alpha, beta-
unsaturated moiety in the chain elongation intermediates plays a role in cyclization, and 
non-natural extender units have the potential for further increasing the diversity of 
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products generated by the pikromycin PKS.2,20-23  Further discussion of the pikromycin 
PKS can be found in several reviews.2,3,24 
A flexible glycosyl-transferase encoded by DesVII is responsible for appending a 
desosamine sugar on both 10-deoxymethynolide and narbonolide to produce the 
immature macrolide antibiotics YC-17 and narbonolide.17  Finally a remarkable tailoring 
enzyme, PikC is responsible for the production of the mature macrolides.  PikC is capable 
of both singly or doubly hydroxylating both immature macrolides YC-17 and 
narbonolide.17,25  In the 12-membered macrolide series, methymycin and neomethymycin 
are the singly hydroxylated products with novamethymycin resulting from double 
hydroxylation.26  In the 14-membered macrolide series, pikromycin and neopikromycin 
are the singly hydroxylated macrolides, and novapikromycin is the product of double 
hydroxylation as demonstrated by Figure 1. 27  
Figure 1.  Pikromycin biosynthetic pathway 
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During xenobiotic metabolism, several promiscuous P450 enzymes are capable of 
a diverse set of transformations, including activation of C-H bonds with pKa’s above 50 
and bond dissociation energies (BDEs) above 110 kcal mol-1!28,29  Catabolic P450 
enzymes often have rigid substrate specificity as demonstrated by the canonical 
erythromycin biosynthetic pathways;30 albeit mutagenesis has expanded the native 
rigidity.31  In contrast, the pikromycin biosynthetic pathway encodes for PikC, a 
cytochrome P450, possessing native substrate flexibility.25  Promising preliminary efforts 
towards development of PikC as a general biocatalyst have been reported including 
preparation of a more active mutant,32 use of an immobilized variant of PikC in 
microfluidic devices,33 demonstration of activity against non-canonical substrates,34 and 
engineering of a self-sufficient fusion protein.35  Unfortunately, a detailed mechanistic 
understanding of the hydroxylation pattern has thus far not been developed. We endeavor 
to explicate a series of rules governing PikC catalyzed hydroxylations and a general 
understanding of the mechanism of this unique P450 enzyme. 
CYTOCHROME P450 BACKGROUND 
 
Cytochrome P450 enzymes are found in nearly all organisms; several thousands 
are known and many more are reported annually.  An arbitrary cutoff has been 
established to denote an enzyme as a cytochrome P450.  When aligned correctly, 
approximately > 40 % identity is required to define an enzyme as a member of the family, 
and a high identity (>55 %)  is required to be a member of a subfamily.36  Bacterial 
variants have served as the model system because bacterial P450s are typically soluble, 
monomeric proteins as opposed to the membrane bound mammalian, plant, and fungal 
proteins.37  Seminal studies were conducted with CYP101 (P450cam) from Pseudomonas 
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putida.38,39  The diversity of reactions catalyzed by P450 has resulted in the moniker  
“Nature’s most versatile biological catalyst.”40  
 The name cytochrome P450 is derived from the presence of a heme (iron 
protoporphyrin IX) group within the protein prosthetic group coordinated on the proximal 
side by a thiolate ion.41,42  Due to this feature, cytochrome P450 enzymes have a 
characteristic spectroscopic signature; a Soret absorption maximum at ~450 nm.42 
Although all member of the cytochrome P450 family contain a thiolate-coordinated heme, 
not all proteins with a thiolate-coordinated heme are in the P450 family, e.g. 
chloroperoxidase.42,43   
 The defining reaction for cytochrome P450 enzymes is the reductive activation of 
molecular oxygen; P450 enzymes are able to insert one of the oxygen atoms of molecular 
oxygen into a substrate, and the other oxygen atom is converted into a water molecule.   
Typically, the electrons are supplied by reduced pyridine nucleotides (NADH or 
NADPH).  Whereby the overall equation for the reaction is RH + NAD(P)H + O2 +H+     
--> ROH + NAD(P)+ + H2O.  Typically P450 enzymes belong to the monooxygenase 
class of enzymes because they only insert one oxygen atom into the substrate;37 however 
P450 enzymes are capable of desaturation, carbon-carbon bond scission, and carbon-
carbon bond formation!44-46 
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Figure 2.  Overall catalytic cycle of cytochrome P450 enzymes37 
 The overall catalytic cycle is summarized in Figure 2; albeit controversy exists in 
the mechanism.37  In the resting state, the enzyme is in the ferric state and has a thiolate 
proximal ligand.  The distal ligand is typically a water molecule. 47  Upon substrate 
binding, a displacement of the water ligand occurs; at this point a shift in redox potential 
of the heme iron atom occurs.  The resulting ferrous, substrate-bound protein then binds 
oxygen to yield the ferrous dioxy complex.  The complex is represented as a ferric 
superoxide complex.   A second electron transfer is usually the rate-limiting step of the 
catalytic cycle; exceptions are known.48  The ferric hydroperoxo intermediate is unstable, 
and is protonated, and fragments to give a ferryl intermediate that can be shown as a 
protein radical cation Fe(IV) species or as a Fe(V) species.  This intermediate is known as 
compound I.  Compound I reacts with substrate to produce the hydroxylated species, and 
 8 
after release of product and water binding, the resting state of the enzyme is obtained; 
alternative species are occasionally suggested as responsible for hydroxylating 
substrates.37 
 The Sherman laboratory is interested in developing unique cytochrome P450 
enzymes as biocatalysts.  PikC is a distinctive P450 enzyme not only for its native 
substrate promiscuity, but also for its specificity towards C-H bonds.  A large body of 
literature has been assembled describing the preference for C-H oxidation with P450 
enzymes.  Seminal studies were conducted on oxidation of heptanes by microsomal P450 
enzymes.49  Subjecting 2-methylpropane to P450 C-H oxidation, the observed product is 
almost exclusive hydroxylation at the lone tertiary site, despite the presence of nine 
primary C-H bonds.  The same trend is observed with secondary C-H bonds when 
products are examined from oxidation of n-heptane.  Over four decades of research has 
supported the hypothesis that site of hydroxylation from a cytochrome P450 reaction is 
the C-H bond with the weakest bond strength.  A generally accepted model predicts 
hydroxylation to occur: benzylic or allylic > tertiary > secondary > primary, although 
sterics can occasionally play a role.37,49-52 
 Intriguingly, PikC is able to deftly hydroxylate both an allylic and secondary 
alkane in the native pikromycin biosynthetic pathway.  In addition when non-canonical 
substrates are presented to PikC, C-H oxidation is achieved at unactivated methylene 
positions.34  Understanding and exploiting this unique reactivity pattern into a general 
biocatalyst could enable the rapid generation of un-natural macrolide compounds. 
 Currently, our understanding of PikC has evolved largely due to biochemical and 
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Figure 3.  PikC hydroxylation products 
crystallographic characterizations.32  Based upon co-crystal structures of YC-17 and 
narbomycin bound to PikC we hypothesized that one enzyme could hydroxylate so many 
substrates due to a desosamine-anchoring mechanism.  Whereby the tertiary amine on 
desosamine is responsible for the critical direct contact between the macrolide and the 
enzyme; other contacts seem to be non-specific.  The macrolactone ring in narbomycin is 
bound almost entirely via hydrophobic interactions with amino acid side chains Leu-93, 
Phe-178, Val-179, Ile-239, Met-394, and Ile-395, and three hydrophilic amino acids, 
Glue-246, His-238, and Asn-392.32  In the co-crystal structures no direct hydrogen 
bonding is observed with these residues.  As demonstrated by Figure 3, the allylic 
position is preferentially hydroxylated in narbomycin in approximately a 40:1 ratio over 
the methylene oxidation product.  Despite this product preference, in the co-crystal 
structure, the allylic C12 carbon is positioned 7.1 Å away from the heme iron, whereas 
the methylene position is only 5.3 Å away from the heme iron center.  This difference in 
product preference is in line with expected products considering bond dissociation 
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energies.  The allylic C-H bond is weaker than the methylene C-H bond by 
approximately 16 kcal/mol;53 in addition the position is conjugated to the alpha, beta- 
unsaturated carbonyl group, thus decreasing the activation barrier.  However, when 
considering the 12-membered macrolactone ring YC-17, a different ratio of products is 
observed; approximately a 1:1 ratio is observed between hydroxylation at the allylic 
position to generate methymycin and at the unactivated methylene to generate 
neomethymycin.  Once again, in the co-crystal structure, the macrolactone ring of YC-17 
is almost entirely bound via hydrophobic interactions projecting the more hydrophilic 
surface of the lactone towards the I-helix and is devoid of hydrogen bonding.  The 
binding site for the 12-membered ring lactone overlaps the binding site for the 14-
membered ring, in addition YC-17 has one more amino acid contact, Val-290.  For YC-
17 the C3’ dimethylamino group of the desosamine sugar is sandwiched between two 
carboxyl groups, Glu-85 and Glu-94; in a discrete binding pocket as compared to 
narbomycin. YC-17 is positioned deeper in the protein interior.  Amino acids Trp-74, 
Asn-91, and Glu-94 participate in a network of hydrogen bond contacts with the tertiary 
amine on desosamine.  Hydrophobic contacts are observed via Trp-74, Leu-81, Leu-88.  
In addition, contacts are observed between desosamine and Met-191 and His-238.  Both 
macrolide antibiotics partially mimic the interaction between desosamine and bacterial 
ribosomes.32 
 From the co-crystal structure, insights into the hydroxylation pattern can be 
obtained.  The allylic C10 site is 7.5 Å away from the iron oxo-center; however the 
unactivated methylene is 5.3 Å away.  It is postulated that the closer distance to the heme 
iron center leads to the 1:1 ratio of methymycin to neomethymycin. 
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 Sherman and Li demonstrated the critical role of a salt bridge between PikC and 
the dimethylamino group on desosamine.  A series of mutants were prepared using site-
directed mutagenesis where the Asp-50, Glu-85, and Glu-94 were replaced with alanine 
or glutamine/asparagines followed by functional analysis in vitro.  Briefly, the data 
showed that replacement of the proximal carboxyl group (Glu-94 for YC-17 and Glu-85 
for narbomycin) with an alanine almost completely abolished conversion.  Substitution of 
the distal carboxyl group generated PikC mutants that were similar to wild type PikC.  A 
surprising result was that preparation of the D50N mutant produced a more active variant 
of PikC.32  
 Shortly thereafter the utility of PikC was further advanced by the generation of a 
self-sufficient variant.  In order to active molecular dioxygen, cytochrome P450 enzymes 
utilized redox partners to sequentially transfer two reducing equivalents from NAD(P)H 
to the heme center.37  In vitro reactions on scale are challenging due to this requirement 
of heterologous redox partners.  However self-sufficient P450 enzymes are known.  The 
first identified was P450BM3, which is naturally fused to a eukaryotic-like reductase.54,55  
P450BM3 is a noteworthy enzyme, and is the most efficient P450 enzyme characterized.56   
Elegant studies have been conducted to generate membrane-bound P450 enzymes that 
have been used in vitro;57,58 unfortunately class I biosynthetic P450 enzymes lack a 
universal reductase partner that can be used to engineer self-sufficient P450 enzymes. 
A potential solution manifested with a new class of self-sufficient P450 enzymes from 
Rhodococcus sp. NCIMB 9784, P450RhF was discovered to be naturally fused to a novel 
FMN/Fe2S2 containing reductase partner.59,60  Li and Sherman prepared the first in vitro 
characterization of a single component bacterial biosynthetic cytochrome P450 enzyme 
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fused to RhFRED and demonstrated its catalytic efficiency.  Preparing a fusion protein of 
the PikCD50N resulted in a self sufficient P450 enzyme that was more active than wild 
type PikC in vitro.35  The binding kinetics and analysis of the catalytic binding pocket 
was also reported.61   
 In addition, the desosamine-anchoring hypothesis was evaluated using completely 
unnatural macrocycles covalently bound to a desosamine sugar, termed carbolides.  
Surprisingly, PikC was able to hydroxylate these carbolides in good to modest yield.  
Although in select cases, the overall yield and conversion was suboptimal, these 
substrates could not be hydroxylated using any other traditional means given the 
sensitivity of the tertiary amine.  Peculiarly, PikC hydroxylated the carbolides in a regio-
and stereo-unselective manner as confirmed by authentic standard synthesis.34   
Understanding PikC is a goal of our current studies.  During the course of this 
dissertation, the groundwork for synthesizing substrates for understanding this enzyme, 
PikC will be presented.  A modular and flexible synthetic strategy was developed to 
synthesize analogs of YC-17 that will be utilized to interrogate PikC hydroxylations; with 
the ultimate goal of developing an empirical model to explain hydroxylation catalyzed by 
PikC.  
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Chapter 2 
 
TOTAL SYNTHESIS OF METHYMYCIN AND NEOMETHYMYCIN 
FEATURING CATALYTIC NICKEL MACROCYCLIZATION AND 
BIOCATALYTIC C-H ACTIVATION 
 
Traditional strategies for the preparation of complex molecules have often relied 
on assembly of appropriately oxidized linear substructures, and in cases of macrolides, 
macrolactonization or ring closing metathesis reactions are typically used to synthesize 
the target molecule.62-64  In contrast, macrocylization of less functionalized structures, 
followed by late stage C-H oxidation, provides a potential strategy to increase efficiency 
in synthesis, in addition to allowing more rapid access to novel analogs.65-67  Nature 
utilizes cytochrome P450 enzymes to produce mature macrolide antibiotics through site 
selective C-H oxidation of simpler intermediates.37,40,46  Remarkable advancements have 
been achieved in chemical C-H functionalization reactions.68  However site selective 
chemical C-H activation of complex structures remains a “holy grail” and subject of 
active research.69-74  In contrast, Nature has had the advantage of millions of years of 
evolution to develop cytochrome P450 enzymes with remarkable selectivity; these 
enzymes have considerable promise in organic synthesis.28,34,75-80  Moreover, developing 
selective chemical catalysts for remote functionalization may be guided by understanding 
biological mechanisms and strategies employed by natural product 450 enzymes.81-86  
The Sherman and Montgomery laboratories have independently developed programs 
aimed at utilizing and understanding natural product biosynthesis and developing nickel 
catalyzed reductive couplings.  Studies described in this chapter merge these two 
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strategies in a synergistic fashion to synthesize methymycin and neomethymycin.  
Ultimately the strategy utilized in this total synthesis will allow the synthesis of analogs 
of YC-17 to interrogate PikC catalyzed hydroxylations. 
 Considerable prior art exists in total syntheses of natural products found within 
the pikromycin biosynthetic pathway. The first total synthesis methynolide was achieved 
by Masamune in 1975.87-89   In the decades to follow eight syntheses of methynolide or 
the seco-acid have been reported.  Grieco (formal) ,90 Yamaguchi,91,92 White (formal),93 
Yonemitsu,94-97 and Ditrich98 synthesized the fully oxidized and protected linear 
fragments and utilized acid activation esterification approaches to the lactone; Yonemitsu 
used a Wittig type esterification.  Unconventional approaches to polypropionate 
frameworks were reported by Ireland,99,100 Vedejs,101-103 and Bartlett (formal).104 Ireland 
approaches the framework through elaboration of homo-diels alder derived 
spiroketals.99,100  Vedejs reported elegant sulfur ylide ring expansions to generate 
mercaptan-methynolide precursor which are converted to methynolide via a 
photochemical oxidation.101-103  Bartlett communicated a conceptually similar approach 
as Ireland whereby cyclic ethers are generated via electrophilic cyclization of unsaturated 
alcohols.  Using this methodology he prepares an intermediated in racemic form that 
Ireland prepared in enantioenriched form.104  Most recently, Cossy has disclosed a formal 
synthesis of methynolide.105,106  The more accessible aglycone 10-deoxymethynolide has 
been prepared by total synthesis by Pilli utilizing a Nozaki-Hiyama-Kisha 
macrocyclization107 and Kang utilized ring closing metathesis.108  Methymycin, 
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neomethymycin and novamethymycin were prepared by total synthesis by Kang and 
disclosed in 2009 and 2010.109,110  O’Doherty and Liu reported analogs of YC-17 where 
the sugar was modified and the aglycone was presumably fermentation derived.111   
The classic synthesis by Masamune set the stage for most total syntheses by other 
investigators.  He utilized acid activation macrolactonization to prepare the target 
aglycone of methymycin.  The most notable contribution was added by Yamaguchi 
where he introduced his 2,4,6-trichlorobenzoic acid ‘Yamaguchi reagent’ as the reagent 
for acid activation.  Using the Yamaguchi reagent he was able to improve the yield of 
macrolactonization to a best case of 41 %.  Ditrich utilized the same bond construction 
and Yamaguchi reagent acid activation to prepare the aglycone of methymycin.   
Yonemitsu was the first to recognize and achieve an alternative bond construction to 
produce the aglycone of methymycin.  He utilized an intermolecular esterification 
followed by a Wittig-type cyclization, allowing a much more efficient ring closing 
reaction.  Most recently, Kang has utilized an approach similar to Yonemitsu, whereby 
ring-closing metathesis was utilized to synthesize the aglycone of methymycin.   
 The Kang syntheses represent the state of the art in macrolide total synthesis as 
the current field stands.  Fully oxidized and protected subunits are prepared followed by 
ring closing metathesis to prepare the macrolactone.  While these syntheses are 
impressive for targeting and preparing a complex molecule, the fully oxidized fragments  
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Figure 4.  Fragment synthesis for Kang’s synthesis of methymycin and 
neomethymycin109,110 
 
required for the synthesis are difficult to synthesize and rely on the chiral pool to set key 
stereocenters.  As described in Figure 4, for the key fragment for the synthesis of 
methymycin begins with commercially available (S)-(+)-glycidyl benzyl ether, available 
from Aldrich ($96/gram).  Kang-1 was subjected to a six-step sequence, initially treated 
with methyl magnesium bromide in the presence of copper iodide, followed by protection 
of the alcohol as a MOM-ether.  The benzyl group is removed using using palladium on 
carbon in a hydrogen atmosphere (Pd/C, H2) to unmask the primary alcohol which is 
oxidized to the aldehyde using Swern oxidation.  The resulting aldehyde is treated with 
MeMgBr followed by direct oxidation of the resulting alcohol to yield Kang-2.  A 
chelation-controlled addition of vinyl magnesium bromide to Kang-2, followed by 
removal of the MOM-ether using 6N HCl achieves the appropriately oxidized subunit for 
the synthesis of methymycin, Kang-3, in diastereomerically pure form in 6 % yield over 
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8 steps.109 
 Kang synthesizes the appropriately oxidized fragment for neomethymycin as 
described in Figure 4 beginning with, Kang-4, methyl (R)-(+)-lactate; more reasonably 
priced at $13/gram.  The first step was a PMB protection, followed by a DIBAL-H 
reduction of the methyl ester to Kang-5, which is used in an Evans syn aldol.  The 
resulting secondary alcohol is protected as a TES silyl-ether, followed by removal of the 
Evans chiral auxiliary to yield Kang-6, which is oxidized using Parikh-Doering 
conditions to Kang-7, a Wittig homologation, and removal of TES silyl-ether by HF 
allowed the synthesis of diasteromerically pure protected diol, Kang-8 in 36 % yield over 
8 steps. 
                  
Figure 5.  Retrosynthetic analysis for methymycin and neomethymycin  
DISSERTATION STUDIES 
Late state C-H oxidation may potentially speed up the synthesis of natural product 
analogs.  Although major pharmaceutical companies have phased out natural product 
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programs over the last several years, select companies have been quite successful 
synthesizing and developing natural products as drugs.112-114  A remarkable effort by 
Eisai pharmaceuticals entailing a 62 step total synthesis of a halichondrin analog was 
recently approved by the FDA in 2010 for breast cancer.115  Increasing efficiency of 
natural product synthesis is a highly desirable goal.  Our approach to methymycin and 
neomethymycin is presented in Figure 5.  The final step is PikC catalyzed C-H oxidation.  
The macrolactone core of YC-17 is synthesized using a nickel-catalyzed ynal cyclization 
developed in the Montgomery laboratory.116-119  The key ynal precursor can be 
disconnected to a carboxylic acid and alkyne fragment. 
 In the forward direction, as described in Figure 6, the synthesis of the carboxylic 
acid fragment commenced with methyl (S)-(+)-3-hydroxy-2-methylpropionate, known as 
the (S)-Roche-ester.  Although this sequence begins with a chiral pool reagent, the cost of 
this reagent is only $5/gram.  The Roche ester is protected as a PMB-ether using the 
PMB-trichloroacetimidate, the ester is reduced using LiAlH4, followed by an Appel 
reaction to prepare alkyl iodide 4, in 3 steps and 86 % yield from 1.  Alkyl iodide 4 is 
used in a Myers alkylation reaction using the pseudoephedrine-derived Myers 
auxiliary.120  Followed by removal of the chiral auxiliary using LiNH2•BH3, the resulting 
alcohol is oxidized using using Dess-Martin121 reagent to prepare aldehyde 7.  An Evans 
syn aldol reaction was done using the phenylalanine derived (R)-Evans auxiliary.122  The 
resulting secondary alcohol, 8, is protected as a TBS-silyl ether, and the Evans auxiliary 
is removed using H2O2 and LiOH to prepare carboxylic acid 9 in 9 steps and 39 % overall 
yield from 1.  Our approach paralleled a reported by Kang and colleagues.108   
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Figure 6.  Synthesis of protected carboxylic acid fragment for methymycin synthesis 
 The requisite alkyne fragment was synthesized in an analogous fashion.  An 
Evans syn aldol reaction,122 followed by protection of the secondary hydroxyl as a TBS 
sily ether and removal of the (S)-Evans auxiliary was done using LiBH4 to generate 
alcohol 13.  A Dess-Martin oxidation followed by two step Corey-Fuchs123 
dibromoolefination-elimination afforded alkyne 15 in six steps and 54 % overall yield 
from oxazolidinone 11, as described in Figure 7. 
 
 
Figure 7.  Synthesis of alkyne fragment 
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 With fragments 15 and 9 synthesized, a model system was utilized to probe the 
ability of the nickel catalyzed ynal cyclization to produce the required macrolactone rings.  
Therefore, using commercially available alkyne, 16, an EDCI mediated esterification was 
 
Figure 8.  Nickel catalyzed ynal cyclization (model system) 
used to prepare ester 17.  Removal of the protecting group with DDQ yielded 18 which 
was oxidized to ynal 19 using Dess-Martin reagent.  Compound 19 was not isolated and 
characterized in pure form as chiral alpha branched aldehydes are often unstable. 
Gratifyingly using the previously developed Ni(cod)2-IMes catalyst system,116,118 
macrolactone 20 was prepared in 62 % yield; notably a 5:1 dr was observed at the allylic 
alcohol as described in Figure 8.  During reaction optimization, several different 
combinations were attempted; however after considerable optimization, optimal 
conditions were developed: 30 mol Ni(cod)2, 29 mol % IMes-HCl, and 40 mol % KO-t-
Bu, in 0.01 M THF.   
 Applying this procedure to the fully functionalized carbon framework of YC-17 
was the next goal, as described in Figure 9.  Yamaguchi conditions were required to 
efficiently prepare ester 21, followed by analogous PMB deprotection and oxidation 
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using Dess-Martin reagent to synthesize ynal 22.  Using the previously developed 
cyclization conditions, macrocyclization was achieved using 30 mol % Ni(cod)2, 29 
mol % IMes-HCl, and 40 mol % KO-t-Bu, in 0.01 M THF.  Notably a 4:1 dr was 
observed at the allylic alcohol; however the distereoselectivity is inconsequential as the  
 
Figure 9.  Synthesis of 10-deoxymethynolide featuring catalytic nickel cyclization 
 
next steps involve global deprotection and chemoselective oxidation using MnO2 to 
synthesize 10- deoxymethynolide, 24, in six steps and in 37 % overall yield from 9.   
 With 24 in hand, the end game involved a glycosylation and the penultimate PikC 
catalyzed C-H oxidation as described in Figure 11.  Given the sensitivity of the tertiary 
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Figure 10.  End game in total synthesis of methymycin and neomethymycin 
amine of desosamine, very mild glycosylation conditions developed by Suzuki were 
employed.124  Unfortunately, the reaction requires a large excess of both hafnium and 
silver salts along with a long reaction time, during which the C2’ acetate on desosamine 
is partially deprotected along with starting material.  Analysis of crude material presents 
YC-17, C2’ acetylated YC-17, and 24.  Therefore 24 is subjected to one round of recycle 
and YC-17 is isolated in 71 % yield over two steps.  The final step involves PikC 
catalyzed C-H oxidation to prepare a mixture of methymycin and neomethymycin.  The 
crude material is analyzed using LC-MS and shows over 99 % conversion, and a mixture 
of methymycin and neomethymycin is isolated in 62 % yield. 
 In summary a total synthesis of methymycin and neomethymycin has been 
developed featuring nickel-catalyzed ynal cyclization and biocatalytic PikC C-H 
oxidation.  The synthesis required 18 linear steps (25 total), and was accomplished in 
6.3 % overall yield from the commercial Roche-ester.  The strategy developed during this 
synthesis will be utilized to synthesized analogs to study PikC catalyzed C-H oxidations. 
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Chapter 3 
REGIO-DIVERGENT NICKEL MACROCYCLIZATION 
 Reductive couplings have evolved as powerful methods for the synthesis of 
complex molecules.  Traditionally reductive couplings involved coupling two carbonyl-
type species to form pinicol type products, e.g. McMurry coupling.  The Nicolaou lab 
disclosed a beautiful example in a total synthesis of taxol as described in Figure 11.125 
     
Figure 11.  McMurry coupling in Nicolau’s taxol total synthesis 
A second, more recently developed variant involves a transition metal catalyzed C-C  
         
Figure 12.  Reductive coupling versus alkylative coupling
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bond forming event where a hydrogen atom (reductive coupling) is transferred instead of 
an alkyl group (alkylative coupling) in the reductive elimination step,118 as depicted in 
Figure 12. 
 Several different classes and variants of transition metal catalyzed reductive 
couplings have been developed; alkyllithium promoted couplings are not discussed.126-129  
The major focus will be upon nickel catalyzed reductive couplings.  Briefly, for selected 
examples utilizing titanium see Sato;130-132 which were later extended and expanded by 
Cha,133 and Micalizio.134-137   For selected examples with rhodium, and hydrogen as a 
reductant, see work by Krische.138-142 Select examples of cobalt couplings were 
developed by Cheng.143-145  Nickel catalyzed variants have mostly been developed by 
Montgomery118,119,146 and Jamison;147 although Chang has also developed select variants, 
which were reviewed and are not discussed.145  The methodology has been applied in 
both inter- and intramolecular couplings.  Several variants exist where Ni(cod)2 can be 
complexed with monodentate phosphines or N-heterocyclic carbene (NHC) ligands, and 
reducing agents such as silane, organozinc, organoborane, or vinylzirconium reagents 
have been utilized.  Several complex molecules have been synthesized using 
methodology developed in the Montgomery and Jamison labs,118,119,147 however the focus 
will be upon nickel complexed with N-heterocyclic carbene (NHC) ligands.  Although 
phopshine variants are incredibly powerful and robust reactions, they suffer from one 
major limitation; terminal alkynes are generally not well tolerated, due to competing 
alkyne trimerization.  In addition, recent computational studies have demonstrated that 
ligand structure has moderate impact on product regioselectivity in aldehyde-alkyne 
reductive couplings with Ni(0)-phosphine catalysts and organoborane reducing 
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agents.148,149 
 In 2004, the Montgomery laboratory developed the nickel-N-heterocyclic carbene 
variant with silane reducing agents.  Using this procedure, synthetically useful terminal 
alkynes were tolerated, as demonstrated in macrocylization reactions with both simple 
hydrocarbon frameworks and in a total synthesis of aigialomycin D as depicted in Figure 
13.116,150  The Montgomery synthesis of aigialomycin D and the Jamison synthesis of 
amphidinolide T1, Figure 15, discussed below, represent the previous start of the art 
approach to complex molecules using catalytic transition metal catalyzed reductive 
couplings.  Strongly electronically biased alkynes are used to set the regiochemistry. 
 
Figure 13.  Total synthesis of aigialomycin D featuring a catalytic nickel cyclization 
cyclization using biased substrates 
 
The mechanism of aldehyde-akyne couplings using an N-heterocyclic carbene 
ligand has been examined computationally151 and experimentally152 and is presented in 
Figure 14.  The key step involves formation of the NiII metallacycle.  The regio-
selectivity observed in the reaction is determined during this step.  The observed product 
is postulated to be favored due to its ability to better stabilize developing positive charge 
during metallacycle formation.  The Jamison group disclosed an elegant total synthesis of 
amphidinolide T1 utilizing the previous state of the art solution; the inherent substrate 
bias of aromatic alkynes is used to synthesize the correct regioisomer resulting from 
reductive coupling as described in Figure 15.153 
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Figure 14.  Mechanism of nickel-N-heterocyclic carbene aldehyde alkyne cyclization 
 
The control of regiochemistry in unsymmetrical alkynes remained an unsolved problem 
until very recently in reductive couplings.  The current state of the art prior to the 2010 
disclosure by the Montgomery laboratory was reviewed,154 and experimentally 
documented by Trost and colleagues.155  Briefly, in most cases of successful addition 
reactions, the alkynes that are utilized either possesses a strong electronic or steric bias.   
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Figure 15.  Jamison synthesis of amphidinolide T1 using electronically biased 
substrates153 
 
This substrate control allows products to be prepared in good to excellent regiocontrol; 
unfortunately only a single reioisomeric product is possible.  Alternatively when alkynes 
that do not possess a strong electronic or steric bias are used in alkyne addition reactions, 
poor regioselectivity is observed.  Classes of alkynes that possess either a strong 
electronic or steric bias include aromatic alkynes,118 terminal alkynes118, silyl alkynes,118 
ynamides,156 and conjugated diynes141 and enynes.140,157,158  In processes that utilize these 
classes of alkynes, products can be prepared with good to excellent regiocontrol.  
Another strategy for biasing substrates has involved the utilization of remote directing 
functionality such as alkenes and alcohols in Ni-catalyzed and Ti-promoted 
reactions.154,159-161 
 The Montgomery group envisioned a strategy that would provide a general 
strategy for regiocontrol, whereby the inherent substrate bias could be overridden by 
appropriate catalyst design.  Preliminary studies demonstrated that product regiocontrol 
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could be modestly impacted by ligand structure; albeit regioselectivities were only 
modestly synthetically useful.116,117,162,163 
            
Figure 16.  Reductive macrocyclizations of aldehydes with terminal alkynes 
 
 Studies disclosed in 2010 addressed and rectified the previous limitations; method 
development studies were conducted using heptaldehyde with 2-hexyne.  Briefly the 
results demonstrated that selecting the appropriate ligand allows the desired product 
regiochemistry to be produced.  For example, to generate product when C-C bond 
formation at the less hindered alkyne terminus is desired, the commercially available 
IMes-HCl ligand should be employed.  To generate product when C-C bond formation at 
the more hindered alkyne terminus is desired, commercially available SIPr ligand is a 
good choice; however (±)-DP-IPr is the ideal choice of ligand, especially with terminal 
alkynes.164  A simple steric model as depicted in Figure 18, whereby reorientation of the 
alkyne in π-complexes ultimately governs the regiochemistry of the product.  The Malik, 
Sormunen, and Montgomery 2010 communication describes that with careful 
optimization of ligand structure, the impact of ligand size effect is quite substantial and  
 
Figure 17.  Reversal of regiochemistry based upon selection of ligand 
HOHOSiEt3 Et3SiH
Ni(0), L
Et3SiH
Ni(0), L Et3SiO
n
n n
previously
reported
not previously
accessible
n-Hex
OSiR3
i-Pr
NNMes Mes
Cl
NN
Ph Ph
BF4
i-Pri-Pr
i-Pr i-Pr
Ni(0), R3SiH, KO-t-Bu H
O
n-Hex
i-Pr
H
Ni(0), R3SiH, KO-t-Bu n-Hex
OSiR3
i-Pr
95:5>98:2
 29 
allows the inherent substrate bias to be reversed across a broad range of biased and 
unbiased alkynes. 
 
Figure 18.  Ligand steric model for control of regiochemistry 
 Studies described in this dissertation involve applying the reversal of 
regiochemistry with a complex substrate in a macrocyclization reaction.  Our ultimate 
goal is to understand PikC catalyzed hydroxylations, and a substrate where we have 
altered the role of the position of the olefin, i.e. the allylic position for PikC 
hydroxylations could serve as a useful tool for studying PikC.  In addition, developing a 
macrocyclization reaction allowing the synthesis of substrates with a 1,1- disubstituted 
allylic alcohol would be a highly desirable outcome.  Current state of the art techniques 
involve addition of a prefunctionalized olefins such as in Nozaki-Hiyama-Kishi type 
coupling.  Although NHK couplings are incredibly powerful and are often used in 
complex molecule synthesis, they require the prefunctionalization of the desired olefin, 
followed by macrolactonization.  An example of a Nozaki-Hiyama-Kishi 
macrocyclization to produce an exo-methylene was described in a natural product 
synthesis by Kishi.165  A more contemporary approach to an exo-methylene-allylic 
alcohol within a natural products was disclosed by the Vanderwal group combining the 
power of ring closing metathesis in conjunction with an electrophilic desilylation.166  His 
group has applied this strategy to a wide range of natural products containing this 
motif,167 as described in Figure 19. 
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Figure 19.  Vanderwal and Kishi synthesis of natural products containing an 1,1- 
disubstituted allylic alcohol moiety 
 
Although both of these approaches are beautiful and comprise very robust chemistry, we 
envisioned a direct approach whereby one can disconnect to non-stereodefined starting 
materials.  Our initial goal was to apply this reversal of regiochemistry to our fully 
functionalized carbon skeleton of the 10-deoxymethynolide ynal precursor.  Using the 
Ni(0)-IMes catalyst system, the endo cyclic allylic alcohol was cleanly obtained.  The 
effect to utilizing the (±)-DP-IPr ligand was initially examined with the same model 
system used during the 10-deoxymethynolide synthesis.  Gratifyingly we were able to 
cleanly synthesize the 11-membered exo methylene-containing lactone in 52 % yield as a 
single diastereomer.  Applying these conditions towards the fully functionalized carbon 
skeleton efficiently allowed the synthesis of an 11-membered lactone containing a 1,1- 
disubstituted allylic alcohol in 59 % yield.  Optimized conditions were developed using 
30 mol Ni(cod)2, 29 mol % (±)-DP-IPr, and 40 mol % KO-t-Bu in 0.01 M THF, as 
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described in Figure 20.   
 
Figure 20.  Reversal of regiochemistry in Ni-catalyzed macrocylizations 
Understanding the impact of the ligand requires careful analysis of the mechanism of 
reductive couplings.  During the metallacycle formation, having the alkyne substituent 
positioned next to nickel helps stabilize developing positive charge, and therefore 
terminal alkynes are strongly electronically biased.  The strategy used to reverse this 
strong electronic bias involved positioning large groups on the N-heterocyclic carbene 
and creating a large steric clash between the alkyl group and the carbene ligand.  
Therefore only the small group, an acetylenic hydrogen, can be accommodated as  
depicted in Figure 21.  
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Figure 21.  Rationale for regiochemistry reversal 
CONCLUSIONS  
 The collaboration between the Montgomery and Sherman laboratories uniquely 
allows two laboratories at the cutting edge of two traditionally disparate fields: transition 
metal catalyzed method development/complex molecule synthesis, in addition, 
biosynthesis and biocatalytic chemistry, to work synergistically towards the goal of 
developing more efficient routes to unnatural macrolide analogs.  Studies described 
during this dissertation represent a first step towards this long-term goal.   
A modular and flexible total synthesis of YC-17 has been developed featuring a 
catalytic-nickel ynal cyclization.  Synthetic derived YC-17 was subjected to a biocatalytic 
C-H activation to generate methymycin and neomethymycin. Leveraging key 
intermediates towards a diverted total synthesis168 effort will provide substrates that will 
be utilized in studying hydroxylation pattern in PikC catalyzed reactions.  Ultimately we 
hope to develop a series of rules governing PikC C-H oxidations, and applying this 
knowledge towards the development of more efficient routes towards analogs of 
macrolide antibiotics.  In addition studies described in this dissertation demonstrated that 
electronically biased complex substrates can have their inherent bias overridden by 
appropriate choice of catalyst.  Substrates synthesized using this general scheme may 
provide an avenue to understanding PikC. 
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In addition, we have developed an efficient approach to the 1,1- disubstituted 
allylic alcohol moiety; however we have only demonstrated this application in two 
complex substrates.  Future students in the Montgomery laboratory will examine the 
generality of these findings towards a range of macrocycles containing limited 
functionality and ring size.  A general method to this motif would be a highly desirable 
outcome. 
Future students in the Sherman-Montgomery laboratory will synthesize substrates 
to probe the hydroxylation pattern in PikC.  A general and modular strategy has been 
developed and can be leveraged to reach substrates that can be utilized to interrogate 
PikC reactivity patterns.  One proposed substrate is presented in Figure 22. 
          
Figure 22.  Proposed analog of YC-17.  
 In conclusion, a total synthesis of methymycin and neomethymycin has been 
achieved whereby a simpler starting material was transformed utilizing an enzyme to 
reach fully oxidized final natural products.  All previous approaches to 
methymycin/neomethymycin have utilized the strategy whereby fully oxidized and 
protected subunits were coupled together followed by macrocyclization and deprotected 
to produce a final natural product.  In addition we have applied a nickel catalyzed 
macrocyclization utilizing stereo-undefined alkynes to prepare stereo-defined allylic 
alcohols along with a novel nickel catalyzed macrocyclization to produce 1,1-
O
O
O
O OHO
NMe2
O
O
O
O OHO
NMe2
H
YC-17 Proposed analog
 34 
disubstituted allylic alcohol containing motifs.  Previous approaches utilized 
prefunctionalized olefins or a multi-step synthesis.   
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Chapter 4 
EXPERIMENTAL           
 
(S)-methyl 3-((4-methoxybenzyl)oxy)-2-methylpropanoate 
To a stirred solution of NaH (0.24 g, 0.010 mmol) in MTBE (75 mL) was added PMB-
OH (12 mL, 101. mmol) (neat and dropwise) and stirred at rt for 90 min.  Subsequently 
re-cooled to 0°C, and trichloroacetonitrile (10.2 mL, 101.6 mmol) was added dropwise.  
The reaction was stirred for 90 min at 0°C, and 30 min at rt.  Solvents were removed 
under reduced pressure.  To the resulting crude mixture, a solution of 0.5 mL of MeOH in 
250 mL of hexanes was added slowly.  Filtered through Celite, solvents were removed 
under reduced pressure, and used directly without further purification. 
 
1 (8.0 g, 68 mmol) was dissolved in 100 mL of cyclohexane, and PPTS (1.7 g, 6.8 mmol) 
was added at rt.  Imidate prepared in previous step was dissolved in CH2Cl2 (25 mL) and 
added via cannula.  The resulting solution was stirred overnight, and TLC indicated an 
incomplete reaction; therefore, additional PPTS (1.7 g, 6.8 mmol) was added and stirred 
for 12 h.  An additional portion of PPTS was added (1.7 g, 6.8 mmol) and stirred for 2 h.  
TLC indicated completion, and crude reaction mixture was filtered through Celite:Silica 
gel bed with 1:5 EtOAc:hexanes, and concentrated under reduced pressure.  The residue 
H3CO
O
OH H3CO
O
OPMB
PMB-trichloroacetimidate, 
PPTS, CH2Cl2:C6H12 
(1:4), 92 %
1 2
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was purified by flash chromatography (1:20 EtOAc:hexanes) to afford the title compound
 (15 g, 92 %) as a colorless oil. Matched all data as previously reported by Boger and 
colleagues.169  
 
  
 
(S)-3-((4-methoxybenzyl)oxy)-2-methylpropan-1-ol 
 
To a suspension of LiAlH4 (4.0 g, 0.11 mol) in Et2O (50 mL) at 0 °C was added a 
solution of 2 (10 g, 44 mmol) in Et2O (50 mL) via cannula.  The resulting solution was 
warmed to rt, and stirred for 18 h.  The solution was cooled to 0°C, and reaction was 
terminated by slow addition of H2O (25 mL), followed by 1N NaOH (25 mL), during 
which grey LiAlH4 was converted into white Al(OH)3, and removed via filtration, 
washed with Et2O (~300 mL), H2O (100 mL) was added, and extracted with EtO2, dried 
with MgSO4, and concentrated under reduced pressure.  The residue was purified by flash 
chromatography (2.5:10 EtOAc:hexanes) to afford the title compound (7.83 g, 98 %) as a 
colorless oil. Matched all data as previously reported by Boger and colleagues.169  
 
 
(S)-1-((3-iodo-2-methylpropoxy)methyl)-4-methoxybenzene 
 
To a stirred solution of 3 (5.4 g, 30 mmol) in CH2Cl2 (150 mL) was added imidazole (5.1 
g, 75 mmol), PPh3 (20 g, 75 mmol), and I2 (15 g, 60 mmol) at 0 °C, and stirred for 10 
HO OPMBH3CO
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2 3
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4
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minutes, allowed to warm to rt, and stirred for 6 h.  The reaction was terminated by 
addition of half saturated Na2S2O3, extracted with ethyl acetate, washed with water, dried 
with MgSO4, and concentrated under reduced pressure.  The residue was dissolved in 
CH2Cl2 and purified by flash chromatography (1:15 EtOAc:hexanes) to afford the title 
compound (8.27 g, 95 %) as a colorless oil. Matched all data as previously reported by 
Carter and colleagues.170 
 
 
(2S,4R)-5-((4-methoxybenzyl)oxy)-N,2,4-trimethyl-N-((2R,3R)-3-phenylbutan-2-
yl)pentanamide 
 
A solution of BuLi (42 mL, 2.5 M) was added to LiCl (11 g, 0.27 mol) and i-Pr2NH (15 
mL, 0.11 mol in THF (10 mL) at -78°C.  The resulting solution was warmed to 0 °C, and 
stirred for 15 min, re-cooled to -78 °C to which an ice cooled solution of 5 (12 g, 53 
mmol) in THF (50 mL) was added via cannula (slowly dripped down side of flask).  The 
mixture was stirred for 1 h at -78 °C, 0 °C for 15 min, rt for 5 min; after which the flask 
is re-cooled to 0 °C.  A solution of 4 (7.7 g, 26 mmol) in THF (10 mL) is added via 
cannula, stirred for 30 min at 0 °C, warmed to rt and stirred for 18 h.  The flask was 
cooled to 0 °C and half saturated ammonium chloride was added, extracted with ethyl 
acetate, washed with water, dried with MgSO4, and concentrated under reduced pressure.  
The residue was purified by flash chromatography (gradient elution from 1:5 
Xc
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LiCl, 85 %
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EtOAc:hexanes to 2:3 EtOAc:hexanes) to afford the title compound (9.4 g, 85 %) as a 
colorless oil. Matched all data as previously reported by Carter and colleagues.170  
 
 
 
(2S,4R)-5-((4-methoxybenzyl)oxy)-2,4-dimethylpentan-1-ol 
 
A solution of BuLi (17 mL, 2.5M) was added to a stirred solution of THF (5 mL) and i-
Pr2NH (6.1 mL, 44 mmol) at -78 °C, and stirred at -78 °C for 10 min, 0°C for 5 min, and 
re-cooled to -78 °C.  A separate flask was charged with BH3•NH3 (1.4 g, 44 mmol) and 
cooled to -78 °C, and previously prepared solution of LDA was added via cannula.  The 
resulting solution was warmed to 0 °C and stirred for 20 min.  The cooling bath was 
removed, and resulting solution was warmed to rt, and stirred for 20 min during which 
the solution became easy to stir, and was re-cooled to 0°C, and 6 (4.5 g, 11 mmol) in 
THF (25 mL) was added via cannula, stirred for 20 minutes at 0°C, the cooling bath was 
removed and stirred at rt for 2 h.  The reaction was terminated by addition of 3N HCl 
(added slowly), extracted with EtOAc, washed combined organic extracts with 2N 
NaOH, water, dried with MgSO4, and concentrated under reduced pressure.  The residue 
was purified by flash chromatography (1:5 EtOAc:hexanes) to afford the title compound 
(2.5 g, 90 %) as a colorless oil. Matched all data as previously reported by Sherman and 
colleagues.7  
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(2S,4R)-5-((4-methoxybenzyl)oxy)-2,4-dimethylpentanal 
 
A solution of ARS-1 (1.4 g, 5.6 mmol) and NaHCO3 (2.4 g, 29 mmol) in CH2Cl2 (70 mL, 
non anhydrous) was cooled to 0 °C, and DMP (3.0 g, 8.4 mmol) was added slowly and 
stirred for 3 h.  The reaction was terminated by addition of a 1:1 solution of half-saturated 
aqueous Na2S2O3 and half-saturated aqueous NaHCO3 and vigorously stirred for 0.5 h, 
extracted with CH2Cl2, washed with half-saturated aqueous NaHCO3, half-saturated 
NaCl, water, dried with MgSO4, and concentrated under reduced pressure.  The residue 
was purified by flash chromatography (1:5 EtOAc:hexanes) to afford the title compound 
(1.3 g, 92 %) as a colorless oil. Matched all data as previously reported by Kang and 
colleagues.172  
 
 
(R)-4-benzyl-3-((2R,3S,4S,6R)-3-hydroxy-7-((4-methoxybenzyl)oxy)-2,4,6-
trimethylheptanoyl)oxazolidin-2-one 
 
To a solution of Xc2 (1.6 g, 6.84 mmol) in CH2Cl2 (30 mL) at 0 °C, was added neat 
dibutylboron triflate (2.3 mL, 9.10 mmol), and stirred for 15 min.  The solution was 
cooled to -78 °C, i-Pr2NEt (1.6 mL, 9.1 mmol) was added drop-wise, stirred for 15 min, 
warmed to 0 °C, and stirred for 1 h, followed by cooling to -78 °C. An ice-cooled 
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O
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solution of 7 (1.1 g, 4.6 mmol) in CH2Cl2 (5 mL) was added drop-wise (dripped down 
side of flask).  The solution was stirred at -78 °C for 2 h, at -20 °C for 1 h, and was 
terminated by addition of pH = 7 phosphate buffer.  To this cloudy solution was added 50 
mL of (1:3) 30 % hydrogen peroxide:MeOH solution, the reaction vessel was removed 
from cooling bath and stirred for 3 h at rt, extracted with CH2Cl2, washed with half-
saturated NaCl solution, water, dried with MgSO4, and concentrated under reduced 
pressure.  The residue was purified by flash chromatography (3.5:10 EtOAc:hexanes) to 
afford the title compound (1.8 g, 82 %) as a colorless oil. Matched data as previously 
reported by Kang and colleagues.172  
 
 
(R)-4-benzyl-3-((2R,3S,4S,6R)-3-((tert-butyldimethylsilyl)oxy)-7-((4-
methoxybenzyl)oxy)-2,4,6-trimethylheptanoyl)oxazolidin-2-one 
 
To a solution of 8 (1.5 g, 3.1 mmol) in CH2Cl2  (40 mL) at 0 °C was added 2,6-lutidine 
(0.69 mL, 5.9 mmol) and TBSOTf (1.1 mL, 4.7 mmol).  The reaction mixture was stirred 
at 0 °C for 4 h, terminated by addition of half-saturated aqueous NaHCO3, and allowed to 
warm to rt.  Extracted with CH2Cl2, washed with half-saturated aqueous NaHCO3, half-
saturated NaCl solution, water, dried with MgSO4, and concentrated under reduced 
pressure.  The residue was purified by flash chromatography (1:10 EtOAc:hexanes) to 
afford the title compound (1.7 g, 92 %) as a colorless oil. Matched data as previously 
reported by Kang and colleagues.172 
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(2R,3S,4S,6R)-3-((tert-butyldimethylsilyl)oxy)-7-((4-methoxybenzyl)oxy)-2,4,6-
trimethylheptanoic acid 
 
To a solution of ARS-2 (0.71 g, 1.2 mmol) in (4:1) THF:water (2 mL) to  was added 30% 
H2O2 (600 µL) and 0.8M LiOH (0.08 g, 1.9 mmol) at 0 °C and stirred for 5 h, quenched 
by adding aqueous Na2SO3 (1.3 M, 3 mL) and half-saturated aqueous NH4Cl (4 mL).  
Extracted with ethyl acetate, dried with MgSO4, and concentrated under reduced 
pressure.  The residue was purified by flash chromatography (2.5:10 EtOAc:hexanes) to 
afford the title compound (0.44 g, 85 %) as a colorless oil. Matched data as previously 
reported by Kang and colleagues.172  
 
 
 
 
(S)-4-benzyl-3-((2S,3R)-3-hydroxy-2-methylpentanoyl)oxazolidin-2-one 
 
To a solution of 11 (12 g, 52 mmol) in CH2Cl2 (75 mL) at 0 °C was added Bu2BOTf (20 
mL, 78 mmol), and stirred for 5 min, followed by slow addition of i-Pr2NEt (18 mL, 0.10 
mol).  The resulting mixture was stirred at 0 °C for 30 min followed by cooling to -78 °C.  
A solution of propanal (7.6 mL, 0.10 mol) in CH2Cl2 (5 mL) was added slowly (dripped 
down side of flask), and stirred at -78 °C for 30 min, and 1 h at 0 °C.  Reaction was 
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terminated by addition of pH = 7 phosphate buffer, followed by slow addition of a 30 % 
H2O2:MeOH (1:3, 40 mL), and stirred at rt for 3 h, extracted with ethyl acetate, washed 
with half-saturated aqueous NaCl, dried with MgSO4, and solvents were removed under 
reduced pressure. The crude solid was recrystallized using EtOAc:hexanes (1:2) solvents 
were removed from mother liquor and the residue was purified by flash chromatography 
(3:20 EtOAc:hexanes) to afford title compound as a colorless solid, (13 g, 86%).  
Matched data as reported by Evans and colleagues.173  
 
 
(S)-4-benzyl-3-((2S,3R)-3-((tert-butyldimethylsilyl)oxy)-2-
methylpentanoyl)oxazolidin-2-one 
 
To a solution of ARS-3 (9.2 g, 32 mmol) in CH2Cl2 (115 mL) at 0°C was added 2,6-
lutidine (7.4 mL, 64 mmol) and TBSOTf (16 mL, 64 mmol).  The reaction mixture was 
stirred at 0°C for 4 h, quenched with half-saturated aqueous NaHCO3, and allowed to 
warm to rt.  Extracted with CH2Cl2, washed with half-saturated aqueous NaHCO3, half-
saturated NaCl solution, water, dried with MgSO4, and concentrated under reduced 
pressure.  The residue was purified by flash chromatography (1:5 EtOAc:hexanes) to 
afford the title compound (13 g, 99 %) as a colorless oil. 1H NMR (500 MHz, CDCl3) δ 
7.35-7.21, (m, 5H), 4.60 (ddd, J = 3, 6.5, 9.5 Hz, 1H), 4.18-4.14 (m, 2H), 3.96 (app. q, J 
= 5.5, 11 Hz, 1H), 3.89 (app. q, J = 6.5, 11Hz, 1H), 3.31 (dd, J = 3, 13.5 Hz, 1H), 2.77 
(dd, J = 9.5, 13 Hz, 1H), 1.61-1.53 (m, 2H), 1.21 (d, J = 7.0 Hz, 3H), 0.91-0.88 (m, 12H), 
0.03 (s, 3H), 0.01 (s, 3H)13C NMR (126 MHz, CDCl3) δ 175.59, 153.27, 135.61, 129.67, 
129.15, 127.53, 73.98, 66.19, 56.03, 42.44, 37.82, 28.35, 26.02, 18.26, 11.67, 9.58, -3.94, 
TBSOTf, lutidine, 99 %
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-4.66. Also reported by Liu, H.-W.174 
  
 
 
 
(2R,3R)-3-((tert-butyldimethylsilyl)oxy)-2-methylpentan-1-ol 
 
To a stirred solution of 12 (4 g, 9.9 mmol) in THF at 0 °C was added MeOH (1.2 mL, 30 
mmol) followed by slow addition of LiBH4 (15 mL, 30 mmol), during which evolution of 
gas was observed.  The resulting mixture was stirred at 0 °C for 10 min, and stirred at rt 
for 2 h.  The reaction was terminated by addition of 1N NaOH (30 mL), poured into 
water (30 mL), extracted with ethyl acetate, washed with half-saturated aqueous 
NaHCO3, half-saturated NaCl solution, water, dried with MgSO4, and concentrated under 
reduced pressure.  The residue was purified by flash chromatography (1:5 
EtOAc:hexanes) to afford the title compound (2.0 g, 89 %) as a colorless oil. Matched 
data as previously reported by Das, P.175 
 
 
 
 
 
(2S,3R)-3-((tert-butyldimethylsilyl)oxy)-2-methylpentanal 
 
To a solution of 13 (1.1 g, 4.7 mmol) and NaHCO3 (1.9 g, 24 mmol) in CH2Cl2 (30 mL, 
non anhydrous) cooled to 0°C, was added DMP (3.2 g, 7.5 mmol) (slowly added portion 
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wise) and stirred for 3 h.  The reaction was terminated by addition of a 1:1 solution of 
half-saturated aqueous Na2S2O3 and half-saturated aqueous NaHCO3 and vigorously 
stirred for 0.5 h, extracted with CH2Cl2, washed with half-saturated aqueous NaHCO3, 
half-saturated NaCl, water, dried with MgSO4, and concentrated under reduced pressure.  
The residue was filtered through a plug of silica gel (1:5 EtOAc:hexanes) to afford the 
title compound (1.0 g, 94%) as a colorless oil. The title compound was used immediately 
as chiral alpha branched aldehydes tend to be unstable. 
 
 
 
tert-butyl((3R,4R)-6,6-dibromo-4-methylhex-5-en-3-yloxy)dimethylsilane 
 
To a solution of PPh3 (2.3 g, 8.2 mmol) and Zn dust (0.54 g, 8.2 mmol) in 50 mL of 
CH2Cl2 was added CBr4 (2.7 g, 4.1 mmol) and stirred for 15 min at rt.  A solution of 
ARS-4 (0.94 g, 4.1 mmol) in 10 mL of CH2Cl2 was added drop-wise, and stirred for 18 h, 
poured into hexanes, filtered through Celite and purified by flash chromatography (100 % 
hexanes) to afford title compound as a colorless oil (1.3 g, 85%). 1H NMR (500 MHz, 
CDCl3) δ 6.30 (d, J = 9.5 Hz, 1H), 3.53 (app. q, J = 5.5, 1H), 2.54 (dquint., J = 2.5, 7.0 
Hz, 1H), 1.45 (m, 2H), 0.95 (d, J = 6.5 Hz, 3H), 0.89 – 0.85 (m, 12H), 0.03 (s, 3H), 0.02 
(s, 3H). 13C NMR (101 MHz, CDCl3) δ 142.7, 87.6, 75.4, 42.4, 27.7, 26.1, 18.3, 13.3, 9.7, 
-4.0, -4.5. HMRS calcd for C13H26Br2OSi [M – H]+ 383.0052, found 383.0041. 
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tert-butyldimethyl(((3R,4R)-4-methylhex-5-yn-3-yl)oxy)silane 
 
To a solution of 14 (1.60 g, 4.1 mmol) in THF (40 mL) cooled to -78 °C was added butyl 
lithium (7.0 mL, 2.4M) drop-wise.  Reaction was stirred at -78 °C for 3 h and 0 °C for 3 
h, terminated by addition water, extracted with ethyl acetate, washed with half-saturated 
NaCl, water, dried with MgSO4, and concentrated under reduced pressure.  The residue 
was purified by flash chromatography (1:20 EtOAc:hexanes) to afford the title compound 
(0.89 g, 89%) as a colorless oil. 1H NMR (500 MHz, CDCl3)  3.58 (app. q, J = 5.5, 11 
Hz) 2.56 (dquint., J = 2.0, 5.6 Hz, 1H), 2.04 (d, J = 2.4 Hz, 1H), 1.74 (m, 1H), 1.58 (m, 
1H), 1.17 (d, J = 7.0 Hz, 3H), 0.92 (m, 12H), 0.09 (s, 3H), 0.07 (s, 3H). 13C NMR (101 
MHz, CDCl3) δ 87.58, 76.26, 69.64, 31.58, 27.41, 26.27, 18.54, 17.41, 9.05, -3.95, -4.14.  
HMRS calcd for C13H26OSi [M – tBu]+ 169.1049, found 169.1052.   
 
 
(2R,3S,4S,6R)-but-3-yn-1-yl 3-((tert-butyldimethylsilyl)oxy)-7-((4-
methoxybenzyl)oxy)-2,4,6-trimethylheptanoate 
 
To a solution of 16 (0.740 g, 1.05 mmol) DMAP (1 crystal), EDCI (0.100 g, 0.522 
mmol), and Et3N (60.0 μL, 0.520 mmol) in 2 mL of CH2Cl2 was added a solution of 9 
(0.183 g, 0.417 mmol) in 0.5 mL of CH2Cl2.  The resulting solution was stirred at rt of 6 
h, and the reaction was terminated by addition of 1N HCl (2 mL), extracted with ethyl 
acetate, washed with half-saturated NaCl, 1N HCl, water, dried with MgSO4, and 
concentrated under reduced pressure.  The residue was purified by flash chromatography 
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(1:10 EtOAc:hexanes) to afford the title compound (0.196 g, 96%) as a colorless oil. 1H 
NMR 1H NMR (400 MHz, CDCl3) 7.24 (d, J  = 8.0 Hz, 2H), 6.86 (d, J  = 8.0 Hz, 2H), 
4.41 (app. t, J = 12.4 Hz, 2H, 4.18-4.07 (m, 2H),  3.81 (app. t, J = 4.8 Hz, 1H), 3.81 (s, 
3H), 3.31 (dd, J = 9.0, 4.6 Hz), 3.13 (dd, J = 7.2, 2Hz, 1H),  2.61 (quint. J = 6.6 Hz, 1H), 
2.50 (dquint. J = 2.8, 7.2 Hz, 2H), 1.98, (t, 2.6 Hz, 1H), 1.85-1.8 (m, 1H), 1.71-1.67 (m, 
1H), 1.56 (s, 3H), 1.43 (ddd, J = 4.8, 8.0, 13.4 Hz, 1H), 1.15 (d, J = 7.2 Hz, 2H), 0.97- 
0.88 (m, 16H), 0.04 (s, 3H), 0.01 (s, 3H).  13C NMR (101 MHz, CDCl3) δ 175.8, 159.2, 
131.1, 129.3, 113.9, 80.3, 75.5, 72.9, 70.1, 62.2, 55.5, 42.4, 37.1, 36.8, 31.2, 26.2, 19.1, 
19.0, 18.5, 16.3, 13.6, -3.9, -4.1.  HMRS calcd for [C28H46O5SiNa]+ 513.3007, found 
555.3009. 
 
                   
(2R,3S,4S,6R)-but-3-yn-1-yl 3-((tert-butyldimethylsilyl)oxy)-7-hydroxy-2,4,6-
trimethylheptanoate 
 
To a solution of 17 (0.178 g, 0.363 mmol) in H2O (0.3 mL) and CH2Cl2 (3 mL) was 
added DDQ (0.164 g, 0.726 mmol) at rt and the resulting solution was stirred for 4 h, 
diluted with CH2Cl2 (5 mL), aqueous half saturated NaHCO3, and extracted with CH2Cl2, 
washed with water, dried with MgSO4, and concentrated under reduced pressure.  The 
residue was purified by flash chromatography (gradient elution from 1:10 EtOAc:hexanes 
to 1:5 EtOAc:hexanes) to afford the title compound (0.124 g, 92%) as a colorless oil. 1H 
NMR 1H NMR (500 MHz, CDCl3) 4.13 (ddddd, J = 7.5, 10.5, 13.3, 17.3, 23.7 Hz, 2H), 
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3.83 (dd, J = 3.5, 6.0 Hz), 3.45-3.37 (m, 2H), 2.63 (quint. J = 7 Hz, 1H), 2.51 (ddd, J = 3, 
7, 9.5 Hz), 1.97 (t, J = 2.5 Hz, 1H), 1.66-1.63 (m, 3H), 1.44 (ddd, J = 5.5, 8.5, 14.0 Hz, 
1H), 1.23 (s, 1H), 1.13 (d, J = 7 Hz, 3H), 0.94-0.87 (m, 16H), 0.04 (s, 3H), 0.01 (s, 3H).  
13C NMR (101 MHz, CDCl3) δ 176.1, 80.3, 70.1, 67.6, 62.4, 42.8, 36.3, 35.8, 33.2, 29.9, 
26.2, 19.1, 18.5, 18.3, 16.9, 14.1, -3.8, -4.0.  HMRS calcd for [C20H38O4Si]+ 370.2539, 
found 370.2540. 
 
 
                 
(2R,3S,4S,6R)-but-3-yn-1-yl 3-((tert-butyldimethylsilyl)oxy)-2,4,6-trimethyl-7-
oxoheptanoate 
 
To a solution of 18 (0.059 g, 0.159 mmol) and NaHCO3 (0.63 g, 0.795 mmol) in CH2Cl2 
(4 mL) at 0 °C was added DMP (0.122 g, 0.287 mmol) in one portion.  The reaction was 
stirred for 4 h at 0 °C, and terminated by addition of 1:1 solution of half-saturated 
Na2S2O3 and half-saturated NaHCO3 (5 mL) and then vigorously stirred for 0.5 h, 
extracted with CH2Cl2, washed with half-saturated NaHCO3, half-saturated NaCl, water, 
dried with MgSO4, and concentrated under reduced pressure to yield crude 19 (0.047 g, 
81 %) as a colorless oil.  The produce was used immediately without characterization as 
chiral alpha branched aldehydes are often unstable. 
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(3R,4S,5S,7R,8S,E)-4-((tert-butyldimethylsilyl)oxy)-3,5,7-trimethyl-8-
((triethylsilyl)oxy)oxacyclododec-9-en-2-one 
In a glovebox Ni(cod)2 (0.005 g, 30 mol %), A (IMes-HCl) (0.006 g, 29 mol %), and KO-
t-Bu (0.002 g, 40 mol %), were charged to a round-bottom flask, removed from the 
glovebox, THF (2 mL) was added and stirred for 10 min at rt.  Neat triethylsilane (17 µL, 
0.11 mmol) was added, followed by syringe drive addition of 19 (0.020 g, 0.054 mmol) 
in THF (2 mL) over three hours, the reaction was stirred for 12 h at rt. The septum was 
removed from the round bottom, stirred for 1 h in open atmosphere.  Solvents were 
concentrated, and the residue was purified by flash chromatography (1:50 
EtOAc:hexanes) to afford the title compound {a 5:1 mixture of C7 diastereomers as 
judged by comparing integration of the signals at 4.90 (major) 4.65 (minor)} (0.026 g, 62 
%) as a colorless oil.  1H NMR (500 MHz, CDCl3) δ 5.56-5.51 (m 1H), 5.3.4-5.28 (m, 
1H), 4-94-4.90 (m, 1H), 4.30-4.26 (m, 1H), 3.99 (dd, J = 5.0 9.0 Hz, 1H), 3.63 (d, J = 9 
Hz), 2.58-2.52 (m, 1H), 2.38-2.33 (m, 3H), 1.73-1.70 (m, 2H), 1.63-1.53 (m, 5H), 1.35-
1.31 (m, 7H), 1.17-1.1 (m, 6H), 0.9-0.86 (m, 37H), 0.56-0.51 (m, 8H), 0.05 (s, 3H), 0.04 
(s, 3H).  Combined integrals for major and minor isomers are reported in regions where 
resolution is poor.   13C NMR (126 MHz, CDCl3) δ  176.4, 131.1, 129.0, 74.2, 68.37, 
60.41, 44.1, 39.0, 32.3, 30.6, 29.3, 29.1, 26.4, 23.2, 18.8, 17.2, 15.5, 14.3, 11.2, 7.1, 5.2, 
1.3, -3.0, -3.1.  All resolved carbon signals for the major and minor diastereomers are 
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reported, and unless noted, integrations refer to mixture of C7 diastereomers. HMRS 
calcd for : C29H58O4Si2  526.3874 found 526.3866. 
 
(2R,3S,4S,6R)-(3R,4R)-4-methylhex-5-yn-3-yl 3-((tert-butyldimethylsilyl)oxy)-7-((4-
methoxybenzyl)oxy)-2,4,6-trimethylheptanoate 
 
To a solution of 48% HF (3.2 mL), MeCN (5 mL), and water (2 mL) at 0 °C was added 
15 (0.64 g, 2.8 mmol), in MeCN (10 mL).  The resulting solution was removed from ice 
bath and stirred at rt for 3 h, and carefully transferred to a separatory funnel, washed with 
half-saturated aqueous NaHCO3, extracted with diethyl ether, dried with MgSO4, and 
concentrated under reduced pressure while cooling flask in an ice bath (CAUTION: 
resulting alkyne was volatile, caution must be exercised when removing solvents).  The 
residue is dissolved in THF, dried with molecular sieves, and used without 
characterization. 
To a solution of 9 (0.22 g, 0.50 mmol) in THF (2 mL) at rt was added i-Pr2NEt (96 µL, 
0.55 mmol), trichlorobenzoyl chloride (78 µL, 0.5 mmol) and stirred for 1 h.  A separate 
flask was charged with B and DMAP (0.122 g, 1.0 mmol) in THF (1.5 mL) and was 
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added via cannula to activated acid.  The resulting solution was stirred for 18 h, quenched 
with aqueous half-saturated NH4Cl, extracted with EtOAc, washed with half-saturated 
aqueous NaCl, dried with MgSO4, and solvents were removed under reduced pressure. 
The residue was purified by flash chromatography (1:10 EtOAc:hexanes) to afford the 
title compound (0.24 g, 92 %) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.24 (d, J 
= 8.8 Hz, 2H), 6.85 (d, J = 8.4 Hz, 2H), 4.71 (app. q, J = 6.0, 1H), 4.39 (s, 2H), 3.88 (dd, 
J = 6.0, 3.2 Hz, 1H), 3.78 (s, 3H), 3.31 (dd, J = 9.2, 4.8 Hz, 1H), 3.10 (app. t, J = 7.4 Hz, 
1H), 2.73 (dquint., J = 2.4, 6.8 Hz, 1H), 2.59 (quint., J = 6.8 Hz, 1H), 2.03 (d, J = 2.8 Hz, 
1H), 1.86-1.76 (m, 2H), 1.74-1.69 (m, 3H), 1.39 (ddd, J = 4.8, 8.0, 13.4 Hz, 1H), 1.14 (d, 
J = 8 Hz, 6H), 0.95 – 0.9 (m, 9H), 0.87-0.86 (m, 9H), 0.034 (s, 3H), 0.026 (s, 3H). 13C 
NMR (101 MHz, CDCl3) δ 175.7, 159.0, 131.0, 129.1, 113.8, 85.1, 76.8, 76.0, 75.4, 72.7, 
70.3, 55.3, 42.6, 36.9, 36.5, 31.1, 29.7, 26.1, 23.7, 18.9, 18.4, 17.2, 16.4, 14.6, 9.6, -4.06, 
-4.08. HMRS calcd for [C31H52O5SiNa]+ 555.3476, found 555.3476.   
 
 
(2R,3S,4S,6R)-(3R,4R)-4-methylhex-5-yn-3-yl 3-((tert-butyldimethylsilyl)oxy)-2,4,6-
trimethyl-7-oxoheptanoate 
 
To a solution of 21 (0.12 g, 0.22 mmol) in water (0.5 mL), and CH2Cl2 (5 mL) at rt was 
added DDQ (0.10 g, 0.45 mmol), the biphasic mixture was stirred for 4 h, diluted with 
CH2Cl2 (5 mL), and washed with aqueous half-saturated NaHCO3, extracted with 
CH2Cl2, washed with water, dried with MgSO4, and solvents were removed under 
O
OPMB
O
OTBS
1. DDQ, CH2Cl2, H2O
2. DMP, NaHCO3, CH2Cl2
2 steps 91%
O
O
O
OTBS
22
H
21
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reduced pressure. The residue was purified by flash chromatography (1:20 
hexanes:EtOAC); however, desired compound co-eluted with anisaldehyde and 
contaminated material was carried forward. 
To a solution of previously prepared mixture in CH2Cl2 (10 mL, non-anhydrous) and 
NaHCO3 (0.092 g, 1.1 mmol), at 0 °C was added DMP (0.168 g, 0.40 mmol) in one 
portion, and was stirred at 0 °C for 4 hours. The reaction was quenched by addition a 1:1 
solution of half-saturated Na2S2O3 and half-saturated NaHCO3 (5 mL) and then 
vigorously stirred for 0.5 h, extracted with CH2Cl2, washed with half-saturated NaHCO3, 
half-saturated NaCl, water, dried with MgSO4, and concentrated under reduced pressure.  
The residue was purified by flash chromatography (1:20 EtOAc:hexanes) to afford the 
title compound (0.082 g, 91 %) as a colorless oil.  1H NMR (400 MHz, CDCl3) δ 9.52 (d, 
J = 2.4 Hz, 1H), 4.69 (ddd, J = 4.8, 6.0, 7.6 Hz, 1H), 3.87 (dd, J = 7.2, 4.0 Hz, 1H), 2.75 
(ddq, J = 2.4, 6.9, 13.0, 1H), 2.62 (quint., J = 7.0 Hz, 1H), 2.42 (m, 1H), 2.04 (d, J = 2.8 
Hz, 1H), 1.84 (ddd, J = 4.0, 8.8, 13.6 Hz, 1H), 1.72- 1.60 (m, 4H), 1.17-1.14 (m, 6H), 
1.08 (d, J = 7.2 Hz, 3H), 0.93 – 0.87 (m, 15H), 0.05 (s, 3H), 0.04 (s, 3H).   
13C NMR (101 MHz, CDCl3) δ 205.3, 175.6, 85.1, 77.2, 76.4, 70.4, 44.3, 43.2, 36.8, 33.2, 
29.8, 26.3, 23.7, 18.6, 17.2, 16.6, 15.0, 14.8, 9.88, -3.79,   -3.84.  HMRS calcd for 
[C23H42O4SiNa]+ 433.2745, found 433.2746.  Note:  Title compound was only isolated 
and characterized as previous compound was impure; chiral alpha branched aldehydes 
are often unstable.  Care should be exercised when handling enantio-enriched aldehydes.   
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(3R,4S,5S,7R,11R,12R,E)-4-((tert-butyldimethylsilyl)oxy)-12-ethyl-3,5,7,11-
tetramethyl-8-((triethylsilyl)oxy)oxacyclododec-9-en-2-one 
In a glovebox Ni(cod)2 (0.007 g, 30 mol %), A (IMes-HCl) (0.008 g, 29 mol %), and KO-
t-Bu (0.004 g, 40 mol %), were charged to a round-bottom flask, removed from the 
glovebox, THF (9 mL) was added and stirred for 10 min at rt.  Neat triethylsilane (27 µL, 
0.17 mmol) was added, followed by syringe drive addition of 22 (0.035 g, 0.085 mmol) 
in THF (1 mL) over three hours, the reaction was stirred for 12 h at rt. The septum was 
removed from the round bottom, stirred for 1 h in open atmosphere.  Solvents were 
concentrated, and the residue was purified by flash chromatography (1:50 
EtOAc:hexanes) to afford the title compound {a 4:1 mixture of C7 diastereomers as 
judged by comparing integration of the signals at 5.00 (major) 5.05 (minor)} (0.026 g, 58 
%) as a colorless oil.  1H NMR (400 MHz, CDCl3) δ 5.66 (dd, J = 15.4, 4.2 Hz, 1H), 5.41 
(dd, J = 15.6, 1.8 Hz, 1H), 5.01 – 4.97 (m, 1H), 4.00 (m, 1H), 3.63 (d, J = 9.6 Hz, 1H), 
2.58 – 2.41 (m, 2H), 1.89-1.85 (m, 1H), 1.80 – 1.76 (m, 2H), 1.67 – 1.48 (m, 5H), 1.34–
1.24 (m, 3H), 1.03 –1.01 (m, 4H), 0.96 – 0.94 (m, 3H), 0.93-0.92 (m, 8H), 0.91-0.89 (m, 
8H), 0.88-0.86 (m, 16H), 0.62 – 0.45 (m, 9H), 0.05-0.04 (m, 9H).  Combined integrals for 
major and minor isomers are reported in regions where resolution is poor.   13C NMR 
(101 MHz, CDCl3) δ 176.2, 131.5, 128.6, 79.5, 77.4, 75.6, 44.1, 37.8, 36.5, 33.6, 32.8, 
26.5, 26.47, 24.9, 20.6, 18.8, 18.4, 17.6, 10.8, 10.6, 7.2, 7.1, 5.22, 5.08, -2.98, -3.09.  
Diagnostic signals for the minor diastereomer include the following: 5.51-5.48 (m, 2H) 
O
OSiEt3
O
OTBSO
O
O
OTBS
Ni(cod)2 (30 mol %), A (29 mol %), 
KO-t-Bu (40 mol %), Et3SiH, 58%, 4:1 dr
N NMes Mes
HCl
A =
22 23a
4:1 at C7
O
OSiEt3
O
OTBS
23b
+
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and 5.10 (m, 1H), and for major diastereomer include 5.66 (dd, J = 15.6, 4.2 Hz, 1H), 
5.41 (dd, J = 15.5, 1.6 Hz, 1H), and 5.01-4.97 (m, 1H).  All resolved carbon signals for 
the major and minor diastereomers are reported, and unless noted, integrations refer to 
mixture of C7 diastereomers. HMRS calcd for : C29H58O4Si2  526.3874 found 526.3866. 
 
 
(3R,4S,5S,7R,11R,12R,E)-12-ethyl-4,8-dihydroxy-3,5,7,11-
tetramethyloxacyclododec-9-en-2-one 
To a solution of 48% HF (0.3 mL), MeCN (0.5 mL), and water (0.2 mL) at 0 °C, was 
added 23a and 23b (0.022 g, 0.042 mmol) in MeCN (0.5 mL).  Reaction was removed 
from cooling bath, and stirred at rt for 3 h.  Diluted with MeCN (5 mL), carefully 
transferred to a separatory funnel, washed with half-saturated aqueous NaHCO3, 
extracted with CH2Cl2, washed with half-saturated NaCl solution, water, dried with 
MgSO4, and concentrated under reduced pressure.  The residue was purified by flash 
chromatography (3:10 EtOAc:hexanes) to afford the title compound {a 5:1 mixture of C7 
diastereomers as judged by comparing integration of the signals at 4.99 (major) 5.09 
(minor)} (0.012 g, 99%) as a colorless oil.  1H NMR (500 MHz, CDCl3) δ 5.71- 5.66 (m, 
1H), 5.50-5.46 (m, 1H), 4.99 (ddd, J = 3.5, 5.0, 8.8 Hz, 1H), 4.14-4.11 (m, 1H), 3.55-3.51 
(m, 1H), 2.59-2.55 (m, 1H), 2.54-2.47 (m, 1H), 1.95-1.87 (m, 2H), 1.69-1.51 (m, 7H), 
1.29-1.21 (m, 8H), 1.05-1.00 (m, 7H), 0.98-0.96 (m, 6H), 0.91-0.84 (m, 5H).  Combined 
integrals for major and minor isomers are reported in regions where resolution is poor.  
O
OSiEt3
O
OTBS
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13C NMR (101 MHz, CDCl3) δ 175.5, 131.2, 128.6, 79.1, 77.4, 76.2, 43.9, 38.0, 35.6, 
32.8, 32.1, 24.6, 20.8, 17.4, 16.7, 11.1, 10.6.  Diagnostic signal for the minor 
diastereomer: 5.09 (ddd, J = 3.0, 5.5, 8.8, 1H) and for major diastereomer is 4.99 (ddd, J 
= 3.5, 5.0, 8.3 Hz, 1H). 
Assignment of stereochemistry at C7 was done by correlation with known compound 
from the Sherman lab7 and from Cane lab.12  
       
 
 
 
(3R,4S,5S,7S,11R,12R,E)-12-ethyl-4-hydroxy-3,5,7,11-tetramethyloxacyclododec-9-
ene-2,8-dione 
 
To a solution of ARS-5a and ARS-5b (0.008 g, 0.027 mmol) in CH2Cl2, was added 
MnO2 (0.047g, 0.54 mmol), and stirred at rt for 2 h.  Filtered through a pad of Celite, 
dried with MgSO4, and concentrated under reduced pressure.  The residue was purified 
by flash chromatography (2.5:10 EtOAc:hexanes) to afford the title compound (0.0066 g, 
82%) as a colorless oil. Matched data as previously reported by Pilli and colleagues.13 
 
 
MnO2, CH2Cl2, 82%
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(3R,4S,5S,7R,11R,12R,E)-4-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-
methyltetrahydro-2H-pyran-2-yl)oxy)-12-ethyl-3,5,7,11-tetramethyloxacyclododec-
9-ene-2,8-dione 
In a glovebox, HfCp2Cl2 (0.064g, 0.17 mmol), AgClO4 (0.035 g, 0.17 mmol), and 4 Å 
powered molecular sieves (0.1 g) were charged to a round bottom flask, the flask was 
removed from the glovebox, CH2Cl2 (2 mL) was added, stirred for 10 minutes, D 
(0.010g, 0.042 mmol) in CH2Cl2 (0.8 mL) was added, and stirred for 0.5 h.  A solution of 
24 (0.005 g, 0.017 mmol) in CH2Cl2 (0.5 mL) was added, and reaction was allowed to stir 
for 48 h, quenched by addition of aqueous half-saturated NaHCO3, extracted with 
CH2Cl2, washed with half-saturated NaHCO3, half-saturated NaCl solution, water, dried 
with MgSO4, and concentrated under reduced pressure.  Analysis of crude reaction 
mixture presented starting material 24, acetylated YC-17 (C2’ on desosamine) and YC-
17.  The residue was purified by flash chromatography (MeOH:CH2Cl2 = 1:50) and 
starting material was subjected to one round of recycle, batches were combined, and 
dissolved in MeOH (1 mL), Et3N (0.5 mL), and water (0.5 mL).  The resulting mixture 
was heated to 40 °C for 3 h, solvents were concentrated, and the residue was purified by 
flash chromatography (2:25 MeOH:CH2Cl2) to afford the title compound (0.005 g, 71%) 
as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 6.71 (dd, J = 5.6, 15.6 Hz, 1H), 6.40 (d, 
O
O
O
O OHO
NMe2
HfCp2Cl2, AgClO4,
D, CH2Cl2
MeOH, Et3N, H2O,
2 steps, 1 recycle,
71%
O
O
O
OH
O
NMe2
AcO
D =
24 YC-17
F
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J = 16.4 Hz, 1H), 4.90 (ddd, J = 2.2, 6.0, 8.2 Hz, 1H), 4.22 (d, J = 7.2 Hz, 1H), 3.56 (d, J 
= 10.4 Hz, 1H), 3.49-3.42 (m, 1H), 3.31-3.23 (m, 1H), 2.83-2.78 (m, 1H), 2.61-2.56 (m, 
1H), 2.50-2.46 (m, 1H), 2.35 (broad s, 6H), 1.77-1.64 (m, 3H), 1.56-1.50 (m, 1H), 1.36 
(d, J = 6.8 Hz, 3H), 1.20 (s, 3H), 1.19 (s, 3H), 1.15-1.13 (m, 3H), 1.1 (d, J = 4.0 Hz, 3H), 
0.96-0.94 (m, 3H), 0.88-0.82 (m, 4H).  13C NMR (101 MHz, CDCl3) δ 205.4, 175.3, 
147.6, 126.2, 104.9, 85.9, 73.9, 70.5, 69.4, 66.3, 45.3, 44.2, 40.6, 38.1, 34.3, 33.7, 29.9, 
29.4, 25.4, 21.3, 17.9, 17.6, 16.3, 10.5, 9.8.  HMRS calcd for : C25H43NO6 [M + H]+ 
454.3163 found 454.3168.  Also reported by Cane and colleagues,9  Isolation of natural 
product YC-17 can be found by: Kinumaki, A.; Suzuki, M.10 
 
 
Mixture of (3R,4S,5S,7R,11S,12R,E)-4-(((2S,3R,4S,6R)-4-(dimethylamino)-3-
hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-12-ethyl-11-hydroxy-3,5,7,11-
tetramethyloxacyclododec-9-ene-2,8-dione and (3R,4S,5S,7R,11R,12S,E)-4-
(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-
yl)oxy)-12-((R)-1-hydroxyethyl)-3,5,7,11-tetramethyloxacyclododec-9-ene-2,8-dione 
 
To a 125 mL Erlenmeyer flask (Caution: DO NOT use a stir bar!) reaction buffer (30 
mL), is added, followed by NADPH (0.043 g in 1 mL of water) and gently swirled, next 
PikCD50NRhFRED (2 mL, with 0.024% being active PikCD50NRhFRED) was added and 
gently swirled, YC-17 (0.002 g), in MeOH (300 µL, CAUTION: MeOH is partially toxic 
to proteins, care must be taken to minimize amount and dilute with reaction buffer) and 
flask was gently swirled.  The flask is placed in a 30 °C incubator overnight.  Protein is 
precipitated by addition of CHCl3 (25 mL).  Crude mixture is filtered through a pad of 
Celite, and concentrated under reduced pressure, and analyzed using LC/MS.  Crude 
O
O
O
O OHO
NMe2
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< 99% conversion,
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reaction mixture analysis by LC/MS indicated approximately a 1:1 ratio between 
methymycin and neomethymycin. The residue was purified by flash chromatography 
(1:10 MeOH:CH2Cl2) to afford the title compound (0.0015 g, 62%) as a colorless oil; 
during purification the mixture was enriched to a 4:3 ratio of 
methymycin:neomethymycin as judged by comparing integration of the signals at 6.76 
(methymycin) and  6.59 (neomethymycin) by integration. Matched data as previously 
reported by Cane and colleagues,11  
 
 
              
 
(+/-)-(1R,2R)-N1,N2-bis(2,6-diisopropylphenyl)-1,2-diphenylethane-1,2-diamine 
 
N-Benzylidene-2,6-diisopropylaniline (10.0 g, 37.7 mmol), magnesium powder (Aldrich 
reagent plus 99.5% purity, 2.75 g, 113 mmol) and of benzene (120 mL) were combined 
in 1.0 L flame dried round-bottom flask with a stir bar under nitrogen. Trifluoroacetic 
acid (17.4 mL, 226 mmol) was then dispensed by syringe drive over 1 h and stirred 
overnight at ambient temperature.  The reaction was terminated with sat. NaHCO3 (250 
mL) and stirred for 1 h. The two layers were separated, and the aqueous layer was 
extracted with EtOAc (3 x 100 mL). The combined organics were then dried with 
Na2SO4 and concentrated under reduced pressure to yield crude brown colored oil. The 
oil was then dissolved in methanol (40 mL) and placed in a freezer (-20  °C) overnight. 
The solvent was then decanted from the precipitate, affording 7.0 g as a mixture of 
NH
PhPh
HN
i-Pr
i-Pri-Pr
i-Pr
racemic
N
Mg(0), THF,
C6H6
 58 
racemic and meso products. The precipitate was then dissolved in refluxing methanol 
(250 mL) and undissolved solids remaining after 1 h were removed by filtration. The 
filtered methanol solution cooled overnight at room temperature. The solvent was then 
decanted from the resulting 2.5 g of white crystalline solid (meso isomer). The mother 
liquor was then concentrated to 125 mL and heated to reflux until all solids dissolved. 
The solution was then cooled to RT and placed in a -20  °C freezer overnight. The 
solvent was decanted to afford 3.2 g of white solid (>98:2 racemic:meso). Matched data 
as previously reported by Sigman and colleagues.14 
       
(±)-(4R,5R)-1,3-Bis(2,6-diisopropylphenyl)-4,5-diphenyl-4,5-dihydro-1H-imidazol-3- 
ium tetrafluoroborate (DP-IPr) 
 
(±)-(1R, 2R)-N1, N2-Bis(2,6-diisopropylphenyl)-1,2-diphenylethane-1,2-diamine (0.580 
g, 0.940 mmol), ammonium tetrafluoroborate (98 mg, 0.94 mmol), triethylorthoformate  
(1.11 g, 7.52 mmol), and formic acid (1 drop) were combined in a dry 25 mL round-
bottom flask with a reflux condenser under nitrogen. The reaction was then heated to 120 
°C with stirring for 24 h. The reaction mixture cooled to room temperature and was then 
concentrated under high vacuum. The reaction mixture was purified by flash column 
chromatography (SiO2, 80% v/v EtOAc/Hexanes, Rf = 0.2) to afford title compound 
(0.530 g, 0.84 mmol, 89% yield) as a pale yellow solid. This material was then heated at 
40 °C overnight, under reduced pressure.  Matched data as previously reported by 
Montgomery and colleagues.15 
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In a glovebox Ni(cod)2 (0.0085 g, 30 mol %), A (0.018 g, 29 mol %), and KO-t-Bu 
(0.004g, 39 mol %), were charged to a round-bottom flask, the flask was removed from 
the glovebox, THF (8 mL) was added and stirred for 10 min at rt.  Neat triethylsilane (33 
µL, 0.21 mmol) was added, followed by syringe drive addition of 22 (0.042 g, 0.103 
mmol) in THF (2 mL) over three hours, the reaction was stirred for 12 h at rt. The septum 
was removed from the round bottom, stirred for 1 h in open atmosphere.  Solvents were 
concentrated, and the residue was purified by flash chromatography (1:50 
EtOAc:hexanes) to afford the title compound  (0.031 g, 59%) as a colorless oil.  1H NMR 
(400 MHz, CDCl3) δ 5.23 (s, 1H), 5.11 (s, 1H), 4.66-4.61 (m, 1H), 3.89 (dd, J = 4.4, 8.0 
Hz, 1H), 3.76 (s, 1H), 2.56 (quintet, J = 7.2 Hz, 2H), 1.87-1.78 (m, 3H), 1.57-1.49 (m, 
1H), 1.42-1.34 (m, 1H), 1.24-1.13 (m, 2H), 1.05-1.00 (m, 5H), 0.94-0.87 (m, 25H), 0.84-
0.83, (m, 2H), 0.58-0.52 (m, 6H), 0.1 (s, 3H), 0.05 (s, 3H).  13C NMR (101 MHz, CDCl3) 
δ 175.3, 147.5, 129.3, 129.0, 112.6, 80.4, 72.5, 64.5, 42.0, 36.7, 31.8, 30.9, 26.4, 26.0, 
18.3, 18.2, 17.3, 15.0, -4.1, -4.3. HMRS calcd for : C29H58O4Si2  526.3874, found 
526.3877.   
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(3R,4S,5S,7R,8S,10R,11R)-4-((tert-butyldimethylsilyl)oxy)-11-ethyl-3,5,7,10-
tetramethyl-9-methylene-8-((triethylsilyl)oxy)oxacycloundecan-2-one 
 
In a glovebox Ni(cod)2 (0.0085 g, 30 mol %), A (0.018 g, 29 mol %), and KO-t-Bu 
(0.004g, 39 mol %), were charged to a round-bottom flask, the flask was removed from 
the glovebox, THF (8 mL) was added and stirred for 10 min at rt.  Neat triethylsilane (33 
µL, 0.21 mmol) was added, followed by syringe drive addition of 22 (0.042 g, 0.103 
mmol) in THF (2 mL) over three hours, the reaction was stirred for 12 h at rt. The septum 
was removed from the round bottom, stirred for 1 h in open atmosphere.  Solvents were 
concentrated, and the residue was purified by flash chromatography (1:50 
EtOAc:hexanes) to afford the title compound  (0.031 g, 59%) as a colorless oil.  1H NMR 
(400 MHz, CDCl3) δ 5.23 (s, 1H), 5.11 (s, 1H), 4.66-4.61 (m, 1H), 3.89 (dd, J = 4.4, 8.0 
Hz, 1H), 3.76 (s, 1H), 2.56 (quintet, J = 7.2 Hz, 2H), 1.87-1.78 (m, 3H), 1.57-1.49 (m, 
1H), 1.42-1.34 (m, 1H), 1.24-1.13 (m, 2H), 1.05-1.00 (m, 5H), 0.94-0.87 (m, 25H), 0.84-
0.83, (m, 2H), 0.58-0.52 (m, 6H), 0.1 (s, 3H), 0.05 (s, 3H).  13C NMR (101 MHz, CDCl3) 
δ 178.8, 152.3, 111.2, 80.3, 80.1, 72.2, 40.0, 36.6, 36.1, 30.9, 30.8, 26.1, 21.7, 19.9, 18.5, 
NN
Ph Ph
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18.3, 16.1, 14.4, 11.7, 7.3, 5.1, -4.4, -4.5. HMRS calcd for : C29H58O4Si2  526.3874, found 
526.3877. 
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APPENDIX 
 
On the forthcoming pages are proton and carbon NMR spectra for compounds 
synthesized during dissertation studies: 
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Please see JACS, 1998, 120, 2682-2683, supporting info for spectral comparison 
and please see Kinumaki, A.; Suzuki, M. for isolation of natural product YC-17.10 
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Crude LC/MS data after reaction mixture was filtered through Celite.  Large Peak 
at 8.5-9.2 minutes is mixture of methymycin and neomethymycin [M + H]+ 470.3   
Peak at 10.6 indicated by arrow is remaining YC-17 [M + H]+ 454.3 
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Purified methymycin and neomethymycin analyzed using FTICR-MS.  Compared 
against standards derived from fermentation.   
 
Lane 1, blank.  Lane 2 contains authentic neomethymycin isolated from 
fermentation.12  Lane 3 contains authentic methymycin isolated from 
fermentation.12  Lane 4 contains synthetic methymycin and neomethymycin 
prepared through total synthesis.   
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Synthetic methymycin and neomethymycin: 
 
Fermentation derived methymycin and neomethymycin: 
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